Edition:
United States

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

8.59USD
23 Feb 2018
Change (% chg)

$0.40 (+4.88%)
Prev Close
$8.19
Open
$8.29
Day's High
$8.65
Day's Low
$8.28
Volume
228,975
Avg. Vol
138,472
52-wk High
$9.69
52-wk Low
$1.89

Chart for

About

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low... (more)

Overall

Beta: --
Market Cap(Mil.): $384.78
Shares Outstanding(Mil.): 44.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share

* PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING

Feb 14 2018

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

Feb 09 2018

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

Feb 09 2018

BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060

* PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING Source text: (http://bit.ly/2oXTLTa) Further company coverage:

Dec 20 2017

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

Dec 07 2017

BRIEF-Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors

* Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors

Nov 21 2017

BRIEF-Pieris Pharmaceuticals reports Q3 loss per share $0.16

* Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update

Nov 08 2017

Earnings vs. Estimates